Prof. B. Wayne Bequette of CBE discusses the challenges and future direction of autologous CAR T-cell therapy, a personalized immunotherapy that reprograms a patient's own T-cells to attack cancer. 

Patient-specific cell therapies offer real hope to patients whose cancers have resisted conventional treatments, but the complex manufacturing processes and patient-specificity pose challenges. Prof. B. Wayne Bequette thinks that automation and AI will accelerate the advancement of CAR T-cell therapy, as will a skilled workforce through the program at the Center for Engineering in Precision Medicine (CEPM) at RPI with the Mount Sinai School of Medicine in New York City.

Full discussion can be found at “CAR T Production Bottlenecks Best Tackled with AI, Automation, and Skilled Staff” in Genetic Engineering and Biotechnology News.